CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

• click to rate

  Posted by Two Blokes May 12 - Filed in Stock - 5 views
  
  - Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) -